Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
- PMID: 29652929
- PMCID: PMC5898760
- DOI: 10.1371/journal.pone.0195897
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
Abstract
Background: Modified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral immunogenic equivalence of three consecutively manufactured MVA production lots, and to confirm the safety and tolerability of MVA focusing on cardiac readouts.
Methods: The trial was conducted at 34 sites in the US. Vaccinia-naïve adults aged 18-40 years were randomly allocated to one of four groups using a 1:1:1:1 randomization scheme. Subjects received either two MVA injections from three consecutive lots (Groups 1-3), or two placebo injections (Group 4), four weeks apart. Everyone except personnel involved in vaccine handling and administration was blinded to treatment. Safety assessment focused on cardiac monitoring throughout the trial. Vaccinia-specific antibody titers were measured using a Plaque Reduction Neutralization Test (PRNT) and an Enzyme-Linked Immunosorbent Assay (ELISA). The primary immunogenicity endpoint was Geometric Mean Titers (GMTs) after two MVA vaccinations measured by PRNT at trial visit 4. This trial is registered with ClinicalTrials.gov, number NCT01144637.
Results: Between March 2013 and May 2014, 4005 subjects were enrolled and received at least one injection of MVA (n = 3003) or placebo (n = 1002). The three MVA lots induced equivalent antibody titers two weeks after the second vaccination, with seroconversion rates of 99·8% (PRNT) and 99·7% (ELISA). Overall, 180 (6·0%) subjects receiving MVA and 29 (2·9%) subjects in the placebo group reported at least one unsolicited Adverse Event (AE) that was considered trial-related. Vaccination was well tolerated without significant safety concerns, particularly regarding cardiac assessment.
Conclusions: The neutralizing and total antibody titers induced by each of the three lots were equivalent. No significant safety concerns emerged in this healthy trial population, especially regarding cardiac safety, thus confirming the excellent safety and tolerability profile of MVA.
Trial registration: ClinicalTrials.gov NCT01144637.
Conflict of interest statement
Figures
Similar articles
-
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.PLoS One. 2016 Jun 21;11(6):e0157335. doi: 10.1371/journal.pone.0157335. eCollection 2016. PLoS One. 2016. PMID: 27327616 Free PMC article. Clinical Trial.
-
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.Lancet Infect Dis. 2021 Apr;21(4):493-506. doi: 10.1016/S1473-3099(20)30476-X. Epub 2020 Nov 17. Lancet Infect Dis. 2021. PMID: 33217361 Clinical Trial.
-
Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.Vaccine. 2017 Mar 23;35(13):1675-1682. doi: 10.1016/j.vaccine.2017.02.032. Epub 2017 Feb 27. Vaccine. 2017. PMID: 28256358 Clinical Trial.
-
Clinical development of Modified Vaccinia virus Ankara vaccines.Vaccine. 2013 Sep 6;31(39):4241-6. doi: 10.1016/j.vaccine.2013.03.020. Epub 2013 Mar 21. Vaccine. 2013. PMID: 23523410 Review.
-
Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Vaccines (Basel). 2023 Aug 24;11(9):1410. doi: 10.3390/vaccines11091410. Vaccines (Basel). 2023. PMID: 37766090 Free PMC article. Review.
Cited by
-
Biological Characteristics and Pathogenesis of Monkeypox Virus: An Overview.Adv Exp Med Biol. 2024;1451:91-109. doi: 10.1007/978-3-031-57165-7_6. Adv Exp Med Biol. 2024. PMID: 38801573 Review.
-
Predicting vaccine effectiveness for mpox.Nat Commun. 2024 May 8;15(1):3856. doi: 10.1038/s41467-024-48180-w. Nat Commun. 2024. PMID: 38719852 Free PMC article.
-
Managing Monkeypox Virus Infections: A Contemporary Review.Iran J Med Sci. 2024 Jan 1;49(1):1-9. doi: 10.30476/IJMS.2022.96738.2837. eCollection 2024 Jan. Iran J Med Sci. 2024. PMID: 38322157 Free PMC article. Review.
-
Quantitative proteomics defines mechanisms of antiviral defence and cell death during modified vaccinia Ankara infection.Nat Commun. 2023 Dec 8;14(1):8134. doi: 10.1038/s41467-023-43299-8. Nat Commun. 2023. PMID: 38065956 Free PMC article.
-
A Review of the Past, Present, and Future of the Monkeypox Virus: Challenges, Opportunities, and Lessons from COVID-19 for Global Health Security.Microorganisms. 2023 Nov 6;11(11):2713. doi: 10.3390/microorganisms11112713. Microorganisms. 2023. PMID: 38004725 Free PMC article. Review.
References
-
- Breman JG, Arita I. The confirmation and maintenance of smallpox eradication. N Engl J Med 1980; 303: 1263–73. doi: 10.1056/NEJM198011273032204 - DOI - PubMed
-
- Mayr A. Smallpox vaccination and bioterrorism with pox viruses. Comp Immunol Microbiol Infect Dis 2003; 26: 423–30. doi: 10.1016/S0147-9571(03)00025-0 - DOI - PubMed
-
- Artenstein AW, Grabenstein JD. Smallpox vaccines for biodefense: need and feasibility. Expert Rev Vaccines 2008; 7: 1225–37. doi: 10.1586/14760584.7.8.1225 - DOI - PubMed
-
- Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970; 122: 303–09. - PubMed
-
- McNeil MM, Cano M, Miller R, Petersen BW, Engler RJ, Bryant-Genevier MG. Ischemic cardiac events and other adverse events following ACAM2000(®) smallpox vaccine in the Vaccine Adverse Event Reporting System. Vaccine 2014; 32: 4758–65. doi: 10.1016/j.vaccine.2014.06.034 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical